Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
— Dr. Morris brings to the Company extensive experience leading the successful development and registration of novel anticancer compounds — WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody
View HTML
Toggle Summary ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that there will be clinical data presentations on two compounds that utilize
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Daniel Junius , President and CEO, will present at the upcoming
View HTML
Toggle Summary ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
Benefit seen in both lenalidomide-naïve and lenalidomide-refractory multiple myeloma WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today
View HTML
Toggle Summary Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Amgen has licensed the exclusive right to use the Company's
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Daniel Junius , President and CEO, will present at the upcoming 31 st
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2013 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Trastuzumab emtansine (T-DM1) marketing applications are under review in the US and Europe ; US application has priority review status with a PDUFA date of February 26, 2013 . In 2013, ImmunoGen expects to report clinical findings with its three lead wholly owned compounds and to advance its fourth
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the following presentations by Company management at upcoming investor
View HTML
Toggle Summary ImmunoGen, Inc. Attains Patient Enrollment Milestone in IMGN901 NORTH Trial
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that it has completed patient enrollment in the first stage of its NORTH two-stage Phase II trial.
View HTML